Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 198

Sort by

Sort Order Select

Journal Articles

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey Jorgensen, Sa A. Wang, Yesid Alvarado, Xuemei Wang, Courtney DiNardo, Lucia Masarova, Tapan Kadia, Rebecca S. Garris, Farhad Ravandi, Hagop Kantarjian

Blood (2024) 143 (5): 417–421.

https://doi.org/10.1182/blood.2023022330

Published: 2024

Includes: Supplemental data

Journal Articles

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

Blood (2022) 140 (16): 1753–1763.

https://doi.org/10.1182/blood.2021014956

Published: 2022

Includes: Supplemental data

Journal Articles

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Mehrnoosh Tashakori, Tapan Kadia, Sanam Loghavi, Naval Daver, Rashmi Kanagal-Shamanna, Sherry Pierce, Dawen Sui, Peng Wei, Farnoosh Khodakarami, Zhenya Tang, Mark Routbort, Carol A. Bivins, Elias J. Jabbour, L. Jeffrey Medeiros, Kapil Bhalla, Hagop M. Kantarjian, Farhad Ravandi, Joseph D. Khoury

Blood (2022) 140 (1): 58–72.

https://doi.org/10.1182/blood.2021013983

Published: 2022

Includes: Supplemental data

Journal Articles

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

Blood (2021) 138 (19): 1885–1895.

https://doi.org/10.1182/blood.2020010603

Published: 2021

Includes: Supplemental data

Journal Articles

Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm

Naveen Pemmaraju, Nathaniel R. Wilson, Joseph D. Khoury, Nitin Jain, Naval Daver, Sherry Pierce, Elias Jabbour, Tapan Kadia, Courtney DiNardo, Guillermo Garcia-Manero, Muzaffar Qazilbash, Marina Konopleva, Hagop Kantarjian

Blood (2021) 138 (15): 1373–1377.

https://doi.org/10.1182/blood.2021011817

Published: 2021

Journal Articles

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Blood (2019) 133 (10): 1011–1019.

https://doi.org/10.1182/blood-2018-10-879429

Published: 2019

Includes: Supplemental data

Journal Articles

Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade

Betul Oran, MDMS, Guillermo Garcia-Manero, MD, Rima M. Saliba, PhD, Gheath Alatrash, DO, PhD, Elias J. Jabbour, MD, Uday Popat, MD, Farhad Ravandi, MBBS, Amin M. Alousi, Tapan Kadia, MD, Marina Konopleva, MD PhD, Courtney D. DiNardo, MDMSc, Sherry Pierce, BSN, BA, Katy Rezvani, MD PhD, Elizabeth J Shpall, MD, Padmanee Sharma, MD PhD, Richard E. Champlin, MD, Hagop M. Kantarjian, MD, Naval Daver, MD

Blood (2017) 130 (Supplement 1): 3209.

https://doi.org/10.1182/blood.V130.Suppl_1.3209.3209

Published: 2017

Journal Articles

Outcomes after Third Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Acute and Chronic Leukemias

Naveen Pemmaraju, MD, Prajwal Boddu, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Marcos De Lima, MD, Richard E. Champlin, MD, Gabriela Rondon, MD, Tapan Kadia, MD, Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Muzaffar H. Qazilbash, MD

Blood (2017) 130 (Supplement 1): 5551.

https://doi.org/10.1182/blood.V130.Suppl_1.5551.5551

Published: 2017

Journal Articles

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Rita Assi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan Kadia, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Nitin Jain, MD, Naval Daver, MD, Taisuke Uehara, Takashi Owa, PhD, Gautam Borthakur, MD

Blood (2017) 130 (Supplement 1): 1380.

https://doi.org/10.1182/blood.V130.Suppl_1.1380.1380

Published: 2017

Journal Articles

JAK3 Variants in Adults with Myeloid Malignancies and Potential for Response to JAK3 Inhibition

Rita Assi, MD, Christopher B Benton, MD, Ahmed Al Rawi, Kamal Chamoun, MD, Feng Wang, PhD, Sherry Pierce, BSN, BA, Keyur P. Patel, MBBS, PhD, Betty K. Hamilton, MD, Courtney D. DiNardo, MDMSc, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Tapan Kadia, MD, Srdan Verstovsek, MD PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 1381.

https://doi.org/10.1182/blood.V130.Suppl_1.1381.1381

Published: 2017

Journal Articles

a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Naval Daver, MD, Rita Assi, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MDMSc, Tapan Kadia, MD, Jing Ning, PhD, Graciela Nogueras González, Sherry Pierce, BSN, BA, Mary Kelly, Weiguo Zhang, MD PhD, Dan Gombos, MD, Steven Kornblau, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 1344.

https://doi.org/10.1182/blood.V130.Suppl_1.1344.1344

Published: 2017

Journal Articles

Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML

Blood (2017) 130 (Supplement 1): 1345.

https://doi.org/10.1182/blood.V130.Suppl_1.1345.1345

Published: 2017

Journal Articles

Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML

Blood (2017) 130 (Supplement 1): 2634.

https://doi.org/10.1182/blood.V130.Suppl_1.2634.2634

Published: 2017

Journal Articles

Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Koji Sasaki, MD, Elias J. Jabbour, MD, Maria Khouri, Deborah A Thomas, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Nicholas J Short, MD, Ghayas C. Issa, MD, Tapan Kadia, MD, Emily Jones, Rebecca Garris, Msc, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD

Blood (2017) 130 (Supplement 1): 2554.

https://doi.org/10.1182/blood.V130.Suppl_1.2554.2554

Published: 2017

Journal Articles

Targeted Therapy for AML Expressing RUNX1 Mutation

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Courtney D. DiNardo, MDMSc, Yimin Qian, PhD, Kanak Raina, PhD, Koichi Takahashi, MD, Tapan Kadia, MD, Dyana T. Saenz, PhD, Agnieszka J Nowak, Baohua Sun, MD PhD, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 2472.

https://doi.org/10.1182/blood.V130.Suppl_1.2472.2472

Published: 2017

Journal Articles

Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2017) 130 (Supplement 1): 2597.

https://doi.org/10.1182/blood.V130.Suppl_1.2597.2597

Published: 2017

Journal Articles

Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis

Naveen Pemmaraju, MD, Bing Z Carter, PhD, Hagop M. Kantarjian, MD, Prithviraj Bose, MD, Tapan Kadia, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MDMSc, Naval Daver, MD, Zeev Estrov, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Lingsha Zhou, Po Yee Mak, Karina Salinas, RN, Carla Kay Tuttle, RN, Sherry Pierce, BSN, BA, Uday Popat, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 256.

https://doi.org/10.1182/blood.V130.Suppl_1.256.256

Published: 2017

Journal Articles

Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase

Nitin Jain, MD, Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Tapan Kadia, MD, William G Wierda, MD PhD, Gautam Borthakur, MD, Kiran Naqvi, MDMPH, Naveen Pemmaraju, MD, Courtney D. DiNardo, MDMSc, Naval Daver, MD, Musa Yilmaz, MD, Keyur Patel, MD PhD, Debra Bull Linderman, RN, Rebecca Garris, Msc, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD

Blood (2017) 130 (Supplement 1): 143.

https://doi.org/10.1182/blood.V130.Suppl_1.143.143

Published: 2017

Journal Articles

Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL)

Blood (2017) 130 (Supplement 1): 1434.

https://doi.org/10.1182/blood.V130.Suppl_1.1434.1434

Published: 2017

Journal Articles

Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL)

Blood (2017) 130 (Supplement 1): 1435.

https://doi.org/10.1182/blood.V130.Suppl_1.1435.1435

Published: 2017

NARROW

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade

Outcomes after Third Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Acute and Chronic Leukemias

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

JAK3 Variants in Adults with Myeloid Malignancies and Potential for Response to JAK3 Inhibition

a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML

Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML

Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Targeted Therapy for AML Expressing RUNX1 Mutation

Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis

Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase

Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL)

Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only